Gout and risk of non-alcoholic fatty liver disease

被引:81
作者
Kuo, C-F [5 ,6 ,7 ]
Yu, K-H [7 ]
Luo, S-F [7 ]
Chiu, C-T [4 ]
Ko, Y-S [3 ]
Hwang, J-S [6 ]
Tseng, W-Y [5 ,7 ]
Chang, H-C [7 ]
Chen, H-W [1 ]
See, L-C [1 ,2 ]
机构
[1] Chang Gung Univ, Dept Publ Hlth, Coll Med, Biostat Consulting Ctr, Tao Yuan 333, Taiwan
[2] Chang Gung Univ, Mol Med Res Ctr, Biostat Core Lab, Tao Yuan 333, Taiwan
[3] Chang Gung Mem Hosp, Div Cardiol, Tao Yuan, Taiwan
[4] Chang Gung Mem Hosp, Div Gastroenterol & Hepatol, Tao Yuan, Taiwan
[5] Chang Gung Univ, Grad Inst Clin Med Sci, Tao Yuan 333, Taiwan
[6] Chang Gung Mem Hosp, Hlth Evaluat Ctr, Tao Yuan, Taiwan
[7] Chang Gung Mem Hosp, Div Rheumatol, Tao Yuan, Taiwan
关键词
GLOMERULAR-FILTRATION-RATE; METABOLIC SYNDROME; SERUM URATE; STEATOHEPATITIS; EXPRESSION; HYPERINSULINEMIA; HYPERURICEMIA; MORTALITY; SODIUM;
D O I
10.3109/03009741003742797
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objectives: To investigate the association between gout and non-alcoholic fatty liver disease (NAFLD). Methods: The study subjects were participants in a health-screening programme at Chang Gung Memorial Hospital from 2000 to 2006. Subjects were classified into eight groups based on serum urate (SU) level and gout status (<= 4.9, 5.0-6.9, 7.0-8.9, and >= 9.0 mg/dL, without and with gout). The association between gout and NAFLD was assessed by multiple logistic regression. Results: Among a total of 54 325 subjects, 1930 (3.6%) had gout and 6169 (11.3%) had NAFLD. The prevalence of NAFLD was significantly higher in subjects with gout (23.1%, n = 445) than in those without gout (10.9%, n = 5724, p < 0.001). Among subjects with NAFLD, the severity of NAFLD was higher in gout patients. Gout was associated with an increased risk for NAFLD [odds ratio (OR) 1.42, 95% confidence interval (CI) 1.25-1.60, p < 0.001], after adjustment for age, sex, presence of metabolic syndrome, and low estimated glomerular filtration rate (eGFR). With SU <= 4.9 mg/dL in the absence of gout as reference, the ORs (95% CI) for NAFLD, after adjustment for age, sex, presence of metabolic syndrome, and low eGFR, were, respectively, 2.16 (1.94-2.41), 3.98 (3.55-4.46), and 5.99 (5.19-6.90) for SU levels 2-4 in those without gout and 2.61 (1.39-4.91), 2.87 (2.04-4.04), 4.53 (3.70-5.56), and 6.31 (5.12-7.77) for SU levels 1-4 in those with gout. Conclusions: There was an independent association between gout and the risk for NAFLD. In addition, there was a dose-response relationship between SU and NAFLD in subjects with and without gout.
引用
收藏
页码:466 / 471
页数:6
相关论文
共 35 条
[1]
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[2]
*BUR HLTH PROM, 2003, CRIT MET SYNDR
[3]
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[4]
Independent impact of gout on mortality and risk for coronary heart disease [J].
Choi, Hyon K. ;
Curhan, Gary .
CIRCULATION, 2007, 116 (08) :894-900
[5]
Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey [J].
Choi, Hyon K. ;
Ford, Earl S. ;
Li, Chaoyang ;
Curhan, Gary .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (01) :109-115
[6]
Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients [J].
Crespo, J ;
Cayón, A ;
Fernández-Gil, P ;
Hernández-Guerra, M ;
Mayorga, M ;
Domínguez-Díez, A ;
Fernández-Escalante, JC ;
Pons-Romero, F .
HEPATOLOGY, 2001, 34 (06) :1158-1163
[7]
Day C P, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS377, DOI 10.1046/j.1440-1746.17.s3.31.x
[8]
Edmison John, 2007, Clin Liver Dis, V11, P75, DOI 10.1016/j.cld.2007.02.011
[9]
Molecular identification of a renal urate-anion exchanger that regulates blood urate levels [J].
Enomoto, A ;
Kimura, H ;
Chairoungdua, A ;
Shigeta, Y ;
Jutabha, P ;
Cha, SH ;
Hosoyamada, M ;
Takeda, M ;
Sekine, T ;
Igarashi, T ;
Matsuo, H ;
Kikuchi, Y ;
Oda, T ;
Ichida, K ;
Hosoya, T ;
Shimokata, K ;
Niwa, T ;
Kanai, Y ;
Endou, H .
NATURE, 2002, 417 (6887) :447-452
[10]
The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation [J].
Hamaguchi, Masahide ;
Kojima, Takao ;
Itoh, Yoshito ;
Harano, Yuichi ;
Fujii, Kota ;
Nakajima, Tomoaki ;
Kato, Takahiro ;
Takeda, Noriyuki ;
Okuda, Junichi ;
Ida, Kazunori ;
Kawahito, Yutaka ;
Yoshikawa, Toshikazu ;
Okanoue, Takeshi .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (12) :2708-2715